8 תוצאות
FIELD OF THE INVENTION
The present invention relates to the use of a retinoid having unique properties for the treatment or prevention of breast cancer or leukemia. More specifically, the present invention relates to the use of 6-[3-[1adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is filed under the provisions of 35 U.S.C. .sctn.371 and claims the priority of International Patent Application No. PCT/EP2015/061641, filed on 27 May 2015 entitled "ANTITUMOR ACTIVITY OF MULTI-KINASE INHIBITORS IN TRIPLE NEGATIVE BREAST
FIELD OF THE INVENTION
This invention relates to novel 4-oxo-butenoic acid derivatives and to the use of these compounds and related compounds with novel biological activity in humans as therapeutic means for the prevention and treatment of the human breast cancer and claims the benefit of priority
FIELD OF THE INVENTION
This invention relates to novel 4oxo-butenoic acid derivatives and to the use of these compounds and related compounds with novel biological activity in humans as therapeutic means for the prevention and treatment of the human breast cancer and claims the benefit of priority
FIELD OF THE INVENTION
This invention relates to novel 4-oxo-butenoic acid derivatives and to the use of these compounds and related compounds with novel biological activity in humans as therapeutic means for the prevention and treatment of the human breast cancer and claims the benefit of priority
FIELD OF THE INVENTION
This invention relates to novel 4-oxo-butenoic acid derivatives and to the use of these compounds and related compounds with novel biological activity in humans as therapeutic means for the prevention and treatment of the human breast cancer and claims the benefit of priority
BACKGROUND OF THE INVENTION
The present invention relates to 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamide derivatives, and to pharmaceutical compositions and methods of treatment of inflammation, cancer and other disorders.
The compounds of the present invention are inhibitors
BACKGROUND OF THE INVENTION
Cancer
Despite many years of research, there exists a compelling need to develop new and more effective therapeutic strategies for cancer. The use of many agents used in cancer treatment is limited because of their cytotoxic effects on normal tissues and cells. This is a